Multi-Agency Nanotech Toxicity Initiative Funded At $105.9 Mil. In FY 2004
This article was originally published in The Gray Sheet
Executive Summary
FDA will continue to monitor potential safety threats associated with some nanotechnology drug delivery devices, according to FDA Associate Commissioner for Science Norris Alderson, PhD